Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics
Pharmaceuticals · 03.04.2025 · 18 (4) · 522
DOI: 10.3390/ph18040522 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 03.04.2025. Verfasst von William Serumula und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, School of Health Sciences, University of KwaZulu-Natal, Durban 4058, South Africa. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fibroblast activation protein (FAP) is a serine protease selectively expressed in cancer-associated fibroblasts (CAFs), fibrotic tissues, and areas of active tissue remodeling, making it an attractive target for diagnostic imaging across a spectrum of disease. FAP inhibitors (FAPIs) labeled with PET tracers have rapidly advanced as a novel imaging modality with broad clinical applications that offers several advantages, including rapid tumor accumulation, low background uptake, and high tumor-to-background ratios. In oncology, FAPI PET has demonstrated excellent performance in visualizing a wide range of malignancies, including those with low glycolytic activity, such as pancreatic cancer, cholangiocarcinoma, and certain sarcomas. Its high sensitivity and specificity for the stromal component enables improved tumor delineation, staging, and response assessment. Additionally, the potential to guide theranostic approaches, where the same tracer can be labeled with therapeutic radionuclides, positions FAPI as a key player in precision oncology. Beyond oncology, FAPI PET has shown promise in imaging conditions characterized by fibrotic and inflammatory processes. In the cardiovascular field, FAPI PET imaging is being investigated for its ability to detect myocardial fibrosis and active cardiac remodeling, crucial in conditions like heart failure, post-myocardial infarction remodeling, and hypertrophic cardiomyopathy. This review highlights the expanding clinical applications of FAPI-based PET imaging across oncology, inflammation, and cardiovascular disease. While the current data are promising, further large-scale studies and multicenter trials are essential to validate these findings and establish standardized protocols. The versatility and broad applicability of FAPI PET underscore its potential as a transformative tool in precision medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, School of Health Sciences, University of KwaZulu-Natal, Durban 4058, South Africa.
ORCID-Profile: Mariza Vorster
Zitieren
APA
Serumula, W., Pillay, V., Hadebe, B., & Vorster, M. (2025). Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics. Pharmaceuticals, 18(4), 522. https://doi.org/10.3390/ph18040522
Vancouver
Serumula W, Pillay V, Hadebe B, Vorster M. Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics. Pharmaceuticals. 2025;18(4):522. doi:10.3390/ph18040522
BibTeX
@article{Serumula2025,
author = {Serumula, William and Pillay, Venesen and Hadebe, Bawinile and Vorster, Mariza},
title = {Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {4},
pages = {522},
doi = {10.3390/ph18040522}
}
EUVIMED